Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Br J Cancer ; 124(5): 860-861, 2021 03.
Article in English | MEDLINE | ID: covidwho-962855

ABSTRACT

Patients with cancer should benefit from COVID-19 vaccination. Some of the most advanced vaccine candidates are mRNAs encapsulated into lipid carriers, and small liposomes are expected to accumulate in tumour tissues through the enhanced and permeation retention effect. However, to what extent solid tumours could take up a significant part of the vaccine dose as well remains unknown. This calls for a careful evaluation of the efficacy of these promising mRNA COVID-19 vaccines administered as lipid carriers for patients with solid tumours, including a possible re-appraisal of the dosing for optimal protection of this specific and frail population.


Subject(s)
COVID-19 Vaccines/administration & dosage , COVID-19/prevention & control , Drug Carriers , Neoplasms/therapy , SARS-CoV-2/immunology , Acceleration , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , COVID-19/epidemiology , COVID-19 Vaccines/adverse effects , Drug Carriers/standards , Frailty/epidemiology , Frailty/therapy , Humans , Immunization Programs/standards , Liposomes/administration & dosage , Liposomes/adverse effects , Neoplasms/epidemiology , Neoplasms/immunology , Pandemics , RNA, Messenger/administration & dosage , RNA, Messenger/standards , Time Factors , Vaccination/methods
SELECTION OF CITATIONS
SEARCH DETAIL